Search Bar & Filters
Found 79 Actively Recruiting clinical trials
Actively Recruiting
This observational study focuses on individuals with Recessive Dystrophic Epidermolysis Bullosa RDEB who were treated with prademagene zamikeracel pz-cel, a gene therapy made from the participants own skin cells and applied surgically to treat wounds. The study aims to evaluate the long-term safety of pz-cel, the durability of wound healing, and the occurrence of any malignancies after treatment in the post-marketing setting. Participants who have received pz-cel treatment will be followed for up to 15 years after their treatment. Assessments will primarily be collected remotely on an annual basis, but if the participants healthcare provider deems it necessary after the first year, some data may be collected during in-person visits. Annual evaluations will include reviewing adverse events, serious adverse events, hospitalizations, evidence of malignancies, potential retroviral infections, wound healing status based on caregiver reports, and any changes in medications or procedures. Throughout the study, participants will provide data annually for up to 15 years post-treatment. Researchers will monitor the number and incidence of treatment-related malignancies, serious adverse events including wound-specific events, and any positive retroviral infection test results. This long-term follow-up aims to understand the safety profile and wound healing durability of pz-cel, with participants contributing data primarily through remote means and occasional in-person assessments as needed.
Actively Recruiting
Researchers are evaluating changes in bone mineral density in premenopausal women with heavy menstrual bleeding caused by uterine fibroids or moderate-to-severe pain from endometriosis. This Phase 3B, open-label study looks at the effects of continuous treatment with a relugolix combination tablet for up to 48 months 4 years, followed by a 1-year period to monitor bone health after stopping treatment. Participants will take a daily oral relugolix combination tablet containing relugolix 40 mg, estradiol 1 mg, and norethindrone acetate 0.5 mg for 4 years. Bone mineral density will be measured every 6 months using dual-energy X-ray absorptiometry DXA. Some women who have completed a previous related study may join to complete 3 years of treatment. After treatment ends, bone density will be checked again at 6 months and 12 months during the follow-up year. Women in the study will have regular visits for bone density scans and health assessments, including physical and gynecological exams, lab tests, and vital signs. Researchers will track changes in bone density at the spine, hip, and femoral neck throughout treatment and follow-up. They will also monitor for any fractures or adverse events during the 4 years of treatment and the 1-year post-treatment period. Total participation can last up to 5 years including the follow-up.
Actively Recruiting
Healthy Volunteer
Researchers are evaluating the safety and immune response of OCU500, a next-generation COVID-19 booster vaccine using a chimpanzee adenovirus vector encoding the SARS-CoV-2 spike protein. This phase 1 randomized, open-label trial involves healthy adults aged 18 to 64 who have completed a primary COVID-19 vaccination series and received at least one booster. The main goal is to assess safety and side effects after a single dose of OCU500. Participants receive one dose of OCU500 at one of two dose levels 1x1010 or 5x1010 viral particles administered either intranasally or via inhalation. The study includes 80 participants divided into four groups of 20 each, with each group receiving a different combination of dose level and administration route. The vaccine is given once on Day 1. Throughout the study, participants undergo safety monitoring including lab tests and tracking of adverse events for up to six months after vaccination. Immune responses are measured by analyzing antibodies in blood and nasal samples at various points up to 181 days. The trial evaluates both local and systemic reactions and collects data on new medical conditions, ensuring thorough follow-up and assessment of vaccine effects over time.
Actively Recruiting
Researchers are evaluating the effectiveness, safety, and tolerability of combining adagrasib with pembrolizumab and platinum-based chemotherapy compared to a placebo combined with pembrolizumab and platinum-based chemotherapy. This study includes participants with previously untreated, locally advanced or metastatic non-squamous non-small cell lung cancer NSCLC who have a KRAS G12C mutation. It is a phase 3, randomized, double-blind trial sponsored by Mirati Therapeutics Inc. Participants will receive either adagrasib plus pembrolizumab plus platinum-doublet chemotherapy or placebo plus pembrolizumab plus platinum-doublet chemotherapy. The chemotherapy agents include carboplatin, pemetrexed, or cisplatin, administered at specified doses on specified days. The study uses a parallel assignment model with quadruple masking. The treatment phase involves these medications, with ongoing monitoring for up to seven years to assess progression-free survival and overall survival. During the trial, participants will undergo regular imaging scans such as CT or MRI to measure disease response according to RECIST v1.1 criteria. Researchers will track outcomes including tumor progression, overall response, duration of response, safety events like adverse and serious adverse events, and quality of life using questionnaires. Safety monitoring continues up to 90 days after the last dose. The total study period may last up to seven years to collect long-term survival and symptom data.
Actively Recruiting
Researchers are evaluating the use of nipocalimab in pregnant individuals at risk for severe Hemolytic Disease of the Fetus and Newborn HDFN. The study aims to compare nipocalimab with a placebo to see if it can reduce the risk of fetal anemia, a condition where the babys red blood cell levels drop too low during pregnancy. This phase 3, randomized, placebo-controlled, and triple-blind study is conducted across multiple centers. Participants will receive either nipocalimab or a matching placebo through weekly intravenous infusions starting from randomization until 35 weeks of gestational age. The study groups include an experimental group receiving nipocalimab and a placebo group receiving an inactive treatment, both administered once weekly. The study timeline spans from randomization during weeks 13 to 18 of pregnancy through delivery and includes follow-up through the neonatal period and beyond. Participants will undergo various assessments including lab tests, fetal DNA testing, and monitoring of maternal and neonatal health outcomes. Researchers will measure the percentage of pregnancies without fetal loss, intrauterine transfusions, hydrops fetalis, or neonatal death, among many other maternal and infant health parameters. Follow-up extends to 104 weeks for some infant assessments, including growth and development, while maternal safety and pregnancy complications are also monitored up to 24 weeks postpartum. This comprehensive monitoring aims to capture the effect of nipocalimab on both mother and baby throughout pregnancy and after birth.
Actively Recruiting
Researchers are evaluating the safety and effectiveness of nipocalimab in reducing the risk of severe fetal and neonatal alloimmune thrombocytopenia FNAIT, a condition affecting unborn and newborn babies. This Phase 3 randomized study compares nipocalimab with intravenous immunoglobulin IVIG treatment in pregnant women at risk of FNAIT. The trial is led by Janssen Research & Development, LLC and focuses on improving outcomes for fetuses and neonates facing serious bleeding risks. Pregnant participants with specific antibodies against HPA-1a andor HPA-5b are randomly assigned to receive either nipocalimab or IVIG. Nipocalimab is given intravenously starting between weeks 13 and 18 of pregnancy until delivery. IVIG is also given intravenously, starting at week 12 for high-risk pregnancies or week 20 for standard-risk pregnancies, along with oral prednisone which is tapered off after delivery based on the doctors judgment or participant tolerance. During the study, participants undergo regular assessments including blood tests to monitor platelet counts in their newborns, evaluation of bleeding events, and tracking of any adverse effects in both the mother and child. The main outcome is the presence of death, severe bleeding, or very low platelet counts in the fetus or newborn up to one week after birth. Longer-term follow-up includes developmental assessments of the infant at one and two years. The total study duration extends up to the end of 2029 with safety monitoring through the first 24 weeks postpartum and infant follow-up for up to 104 weeks.
Actively Recruiting
Researchers are evaluating DMX-200 repagermanium, a drug that blocks a receptor involved in inflammation, in patients with focal segmental glomerulosclerosis FSGS who are also receiving an angiotensin II receptor blocker ARB. This Phase 3 study aims to assess the safety and effectiveness of DMX-200 compared to placebo over two years in adults and adolescents aged 12 to 17 years. The study is led by Dimerix Bioscience Pty Ltd and includes a double-blind period followed by an open-label extension to observe long-term effects. Participants receive either 120 mg of DMX-200 or a matching placebo capsule twice daily for 104 weeks during the double-blind treatment phase. Afterward, those who complete this phase may enter a two-year open-label extension where all participants receive DMX-200 twice daily. The study includes a screening and qualification period lasting 6 to 14 weeks, a possible titration phase, a stabilization phase, and a follow-up period after treatments. Throughout the trial, patients will undergo assessments including urine proteincreatinine ratio and kidney function tests like estimated glomerular filtration rate eGFR at multiple time points up to week 104 and during the extension. Safety and tolerability are closely monitored through regular evaluations, adverse event tracking, and follow-up visits. Total participation may last about 230 weeks, covering all study phases and follow-up periods.
Actively Recruiting
This research aims to study the use of Sulbactam-Durlobactam SUL-DUR in pediatric patients from birth to under 18 years old who have suspected or confirmed infections caused by Acinetobacter baumannii-calcoaceticus complex ABC. The goal is to collect important data on how the drugs behave in the body pharmacokinetics and their safety to find the right dosing for children. The study is open-label and conducted in hospitalized children needing systemic antibiotic treatment for ABC infections. Participants will receive Sulbactam and Durlobactam at doses adjusted by age and weight, administered intravenously every 6 to 12 hours depending on their age group. Different dosing cohorts include children from birth with separate dosing for term and preterm infants up to less than 18 years old. The study is non-randomized and single-group, focusing on measuring drug concentrations on Days 1 and 3 and monitoring safety over 28 days. During the study, participants will have blood samples taken to assess drug levels and various health markers such as liver and kidney function, blood counts, and vital signs from baseline through Day 28. Adverse events and tolerability will be carefully recorded. The total participation lasts until 28 days after dosing to ensure thorough safety and pharmacokinetic evaluation of the treatment in this pediatric population.
Actively Recruiting
Researchers are evaluating the effectiveness of Pumitamig compared to Pembrolizumab in participants with previously untreated advanced Non-Small Cell Lung Cancer NSCLC who have a PD-L1 expression of 50% or higher. This Phase 3, randomized, double-blind study focuses on participants with locally advanced or metastatic NSCLC, aiming to understand which treatment better controls the disease and improves survival outcomes. Participants are randomly assigned to receive either Pumitamig or Pembrolizumab at specified doses on specified days. The study compares these two drugs as first-line treatments for their impact on disease progression and overall survival. The treatment period may last up to approximately five years to assess long-term outcomes. During the study, participants will undergo regular assessments including imaging and symptom questionnaires to evaluate progression-free survival and overall survival. Researchers will also monitor objective response, duration of response, disease control rate, and symptom changes using established criteria. Safety and effectiveness will be closely followed throughout the study, which lasts up to about five years from enrollment.
Actively Recruiting
Researchers are evaluating the effects of a medicine called BI 764198 in adults and adolescents with a kidney disease known as focal segmental glomerulosclerosis FSGS. This Phase 3 study aims to understand whether BI 764198 can help people with primary FSGS or genetic FSGS related to TRPC6 gene mutations. The trial is randomized, double-blind, and placebo-controlled, comparing BI 764198 tablets to placebo tablets. Participants take one tablet daily for up to two years alongside their usual FSGS treatments. They are randomly assigned to either the BI 764198 group or the placebo group, with equal chance to be in either. The study monitors participants over 104 weeks, collecting urine samples regularly to assess kidney function and compare results between groups. During the study, participants visit the study site about every three months for health assessments and safety monitoring. Researchers measure changes in urine protein-creatinine ratio and kidney filtration rate to evaluate treatment response. Additional questionnaires assess disease impact. The total participation time is up to two years, allowing long-term evaluation of the treatments effects and safety.
1-10 of 79
1